Wolwo Pharma Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
1,808
- Stock Symbol
-
300357
- Investments
-
2
- Share Price
-
$3.25
- (As of Friday Closing)
Wolwo Pharma General Information
Description
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is engaged in Research, development, production and sales of biopharmaceutical products.
Contact Information
Website
www.wolwobiotech.comCorporate Office
- Wukang Town
- Deqing County
- Huzhou, Zhejiang 313200
- China
Corporate Office
- Wukang Town
- Deqing County
- Huzhou, Zhejiang 313200
- China
Wolwo Pharma Stock Performance
As of 13-Nov-2026, Wolwo Pharma’s stock price is $3.25. Its current market cap is $1.7B with 524M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.25 | $3.28 | $2.77 - $4.76 | $1.7B | 524M | 10M | $0.12 |
Wolwo Pharma Financials Summary
As of 30-Sep-2026, Wolwo Pharma has a trailing 12-month revenue of $162M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,402,724 | 1,946,139 | 1,307,818 | 1,991,862 |
| Revenue | 162,352 | 147,734 | 128,967 | 119,888 |
| EBITDA | 68,412 | 64,734 | 53,679 | 50,144 |
| Net Income | 62,002 | 52,972 | 44,293 | 43,843 |
| Total Assets | 479,894 | 414,109 | 371,108 | 361,449 |
| Total Debt | 1,812 | 2,631 | 3,505 | 8,809 |
Wolwo Pharma Patents
Wolwo Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230022218-A1 | Method and kit for detecting human papillomaviruses | Pending | 13-Dec-2019 | ||
| EP-4074843-A1 | Method and test kit for detecting human papillomavirus | Active | 13-Dec-2019 | ||
| EP-4074843-A4 | Method and test kit for detecting human papillomavirus | Active | 13-Dec-2019 | ||
| EP-4074843-B1 | Method and test kit for detecting human papillomavirus | Active | 13-Dec-2019 | ||
| EP-4074843-C0 | Method and test kit for detecting human papillomavirus | Active | 13-Dec-2019 | C12Q1/708 |
Wolwo Pharma Signals
Wolwo Pharma Investments (2)
Wolwo Pharma’s most recent deal was a Secondary Transaction - Private with Kaiyi Pharmaceutical. The deal was made on 21-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kaiyi Pharmaceutical | 21-Jul-2021 | Secondary Transaction - Private | Pharmaceuticals | ||
| Kaiyi Pharmaceutical | 30-Sep-2017 | Secondary Transaction - Private | Pharmaceuticals |
Wolwo Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.77 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Wolwo Pharma FAQs
-
When was Wolwo Pharma founded?
Wolwo Pharma was founded in 2002.
-
Where is Wolwo Pharma headquartered?
Wolwo Pharma is headquartered in Huzhou, China.
-
What is the size of Wolwo Pharma?
Wolwo Pharma has 1,808 total employees.
-
What industry is Wolwo Pharma in?
Wolwo Pharma’s primary industry is Pharmaceuticals.
-
Is Wolwo Pharma a private or public company?
Wolwo Pharma is a Public company.
-
What is Wolwo Pharma’s stock symbol?
The ticker symbol for Wolwo Pharma is 300357.
-
What is the current stock price of Wolwo Pharma?
As of 13-Nov-2026 the stock price of Wolwo Pharma is $3.25.
-
What is the current market cap of Wolwo Pharma?
The current market capitalization of Wolwo Pharma is $1.7B.
-
What is Wolwo Pharma’s current revenue?
The trailing twelve month revenue for Wolwo Pharma is $162M.
-
What is Wolwo Pharma’s annual earnings per share (EPS)?
Wolwo Pharma’s EPS for 12 months was $0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process